News

Insilico

Find us here ...

Subscribe to our newsletter

The information included in this website is for informational purposes only: its purpose is to promote a broad consumer understanding a knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

DISCLAIMER FOR U.S. BASED INVESTORS

The Agent of First Longevity Limited in the United States is Marco Polo Securities Inc, a non-affiliated broker-dealer registered with the US Securities and Exchange Commission. The activities of First Longevity Limited in the United States will be affected only to the extent permitted by Rule 15a-6 under the US Securities Exchange Act of 1934 and in accordance with the Services Agreement entered into between First Longevity Limited and Marco Polo Securities Inc with respect thereto. Contact at Marco Polo Securities is clientservices@mpsecurities.com; 1-347-745-6448.

No spam - just the good stuff

More

News

Insilico

Insilico and SRW partner to advance longevity science through power of AI

Insilico uses Microsoft’s BioGPT to find targets for aging and disease

Insilico and University of Cambridge present new approach for discovering targets for Alzheimer’s

Insilico doses first patients in Phase 2 IPF trial

Insilico Medicine files for Hong Kong IPO

Transformer-based aging clock provides insights into aging

Longevity investment bulletin: Kate Therapeutics, Insilico Medicine, Oxford Cryo and more

Longevity investment bulletin: NewLimit, ORA, Insilico Medicine and more

Longevity investment bulletin: Buck Institute, NeuroSense, Form Bio and more

Find us here ...

Subscribe to our newsletter

More